<DOC>
	<DOCNO>NCT01086267</DOCNO>
	<brief_summary>The purpose study identify safe tolerable dose BMS-908662 combination cetuximab ; evaluate tumor response BMS-908662 administer alone combination cetuximab</brief_summary>
	<brief_title>Safety Efficacy Study BMS-908662 Alone Combination With Cetuximab Subjects With K-RAS B-RAF Mutation Positive Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Phase 1 : Single Arm Study Phase 2 : Randomized Controlled , Parallel</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects KRAS ( codon 12 13 ) B RAF ( V600E ) mutation positive advance metastatic colorectal cancer relapse refractory 2 standard systemic anticancer regimes metastatic disease , intolerant exist therapy . Histologic cytologic confirmation diagnosis . Eastern Cooperative Oncology Group ( ECOG ) â‰¤ 1 Adequate organ &amp; marrow function . Uncontrolled significant cardiovascular disease . Phase 2 : Prior therapy RAF inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>